Navigation Links
Nektar Therapeutics Reports First Quarter 2011 Financial Results
Date:4/27/2011

as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.  NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's drug candidate pipeline, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studie
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dennis Winger Joins Nektar Therapeutics Board of Directors
2. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
3. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
5. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
9. Nektar Therapeutics Reports First Quarter 2009 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)... San Francisco, CA (PRWEB) February 27, 2015 ... is joining forces on February 28 with patients and ... to raise awareness for Rare Disease Day®. Rare ... rare diseases and calling attention to the special challenges ... community around them. , “Cytokinetics is proud to stand ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... , ATLANTA, Oct. 27 Craneware ... improvement solutions for U.S. healthcare, today announced a presentation ... Strategies Conference scheduled for November 5-7 in Chicago, IL. ... with more than 30 years experience - Director of ...
... Md., Oct. 27 Precision Antibody(TM) has ... of the National Cancer Institute (NCI),s Clinical Proteomic Technologies ... number and standardizing the quality of monoclonal antibody reagents ... is the result of a third solicitation for contract ...
... Switzerland, Oct. 27 Syngenta Ventures announced today that ... privately-held U.S. biotechnology company focused on the use of ... direct investment by Syngenta Ventures, Syngenta,s newly-established corporate venture ... complement our in-house R&D work and enables us to ...
Cached Biology Technology:Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 2Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 3Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3Syngenta Ventures Invests in U.S. Biotech Company Metabolon 2Syngenta Ventures Invests in U.S. Biotech Company Metabolon 3
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... that could offer a new pathway to restoring vision ... cells in the eye to be light sensitive that ... a gene for a light-sensitive protein into "inner retinal ... that resembles the defect in such inherited human disorders ...
... new 60 and 60 is the new 50, unfortunately for ... it simply isn't true. , New research however from The ... non-pharmaceutical means to maintain muscle function and quality of life ... be as simple as taking a stroll followed by a ...
... Institute, a private laboratory affiliated with the University of Wisconsin-Madison, ... of animal cells and used it to derived two new ... is reported today (Jan. 1, 2006) in the journal Nature ... clinical reality by completely ridding the culture medium in which ...
Cached Biology News:'Prosthetic' retinal cells let blind mice see light 2Chocolate milk could be key to longer, healthier life 2Wisconsin scientists grow two new stem cell lines in animal cell-free culture 2Wisconsin scientists grow two new stem cell lines in animal cell-free culture 3
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine ... It is isolated as the heterodimer of ... has the ability to dephosphorylate the a-subunit ... subunit, PPase-2A has broad substrate specificity and ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... wide variety of solvent vapors that can contaminate and ... allows for the collection of liquid into a self ... waiting period., Ultra low -104 o C ... , Digital Display of temperature ...
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: